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Abstract The widely studied macrophage scavenger receptor
system is known to bind both acetylated low density lipoprotein
and oxidized low density lipoprotein. Although only the latter
ligand has been shown to occur in vivo, acetylated low density
lipoprotein is often used to evaluate the contribution of scavenger
receptors to different (patho)physiologic processes, assuming
that all existing subtypes of scavenger receptors recognise both
lipoproteins. In the present work, we identify human platelets as
the first natural cell type to bind oxidized low density lipoprotein
without showing specificity for acetylated low density lipopro-
tein. Consequently, platelets possess exclusive receptor(s) for
oxidized low density lipoprotein distinct from the ‘classical’
scavenger receptor AI/AII. From the data presented in this work,
we conclude that the class B scavenger receptor CD36 (GPIV) is
responsible for this exclusive oxidized low density lipoprotein
binding.
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1. Introduction
Today, the term scavenger receptor (SR) is synonymous for
receptors that are able to bind chemically modi¢ed low den-
sity lipoprotein (LDL).
The ¢rst modi¢ed LDLs that were shown to speci¢cally
bind to the macrophage SR system were acetylated LDLs
(AcLDLs). Macrophages incubated with AcLDL undergo
characteristic morphological changes due to the unrestricted
uptake of lipoproteins, thereby developing a similarity with a
certain type of cell typical of atherosclerotic lesions, the so-
called foam cell. This is why from an early stage, SRs have
been attributed a possible role in the clinical manifestation of
atherosclerosis.
The ¢nding that LDL develops speci¢city for the SR system
when subjected to oxidative stress was an extremely important
one. It marked the identi¢cation of an in vivo ligand of this
receptor, able to induce the same morphological changes in
target cells as AcLDL.
However, a more detailed examination of the interaction
between acetylated and oxidized LDL with macrophage mem-
brane receptors revealed an unequal level of competition be-
tween AcLDL and oxidized (Ox) LDL. This seemed to indi-
cate the existence of di¡erent types of SRs, some of which are
able to exclusively bind the respective lipoproteins [1,2].
In fact, a number of di¡erent SRs could be identi¢ed in the
past few years. On the basis of a systematic classi¢cation in
mammalian cells, there has been di¡erentiation into class A
(consisting of SR-AI and SR-AII) and class B SRs (consisting
of SR-BI and CD36) (for review see [3]). Further SRs have
been identi¢ed recently, which have not yet been classi¢ed
according to this system [4^6].
A common feature of all SRs is their ability to bind an
unusually broad array of ligands. Nevertheless, as was initially
assumed, di¡erences exist between the respective SRs with
regard to their particular ligand speci¢city.
Paradoxically, the very ¢nding that there is non-reciprocal
cross competition between OxLDL and AcLDL that led to
the speculation that di¡erent types of SRs exist, might, at least
in part, be explained as a consequence of properties of the
receptors themselves [7] and/or the extent of oxidative mod-
i¢cation of the lipoproteins [8].
A whole range of (patho)physiological functions can be
attributed to the SRs thus far discovered. Their most prom-
inent feature is their involvement in the atherosclerotic proc-
ess due to their speci¢city for OxLDL. On the other hand,
SR-BI ful¢lls an important protective function due to its ex-
perimentally veri¢ed central role in reverse cholesterol trans-
port [9,10].
Among all experimentally veri¢ed functions of SRs, the
binding and phagocytosis of apoptotic cells is of particular
interest, as there is evidence that tends to suggest that this
physiologically most important process is mediated by an ex-
clusive OxLDL receptor [11,12].
However, up to the present day, there has been no unequiv-
ocal identi¢cation of such a receptor in vivo. The process of
this identi¢cation is complicated by the fact that there is still
no knowledge of a ‘natural’ cell type (i.e. one that has not
been genetically manipulated) which exclusively binds OxLDL
but not AcLDL. One is therefore dependent on expression
cloning strategies when examining this question although
such strategies seem to result in widely ranging and contra-
dictory results when approaching this very problem.
Furthermore, as AcLDL is often used as an inhibitor to
evaluate the contribution of SRs to various macrophage func-
tions, the identi¢cation of an exclusive OxLDL receptor
would be of pivotal importance, as some of the results ob-
tained with AcLDL would then need to be reassessed.
2. Materials and methods
Carrier-free Na125I was purchased from ICN (Costa Mesa, CA,
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USA). PBS, cell culture media and sera were from BioWhittaker
Europe (Verviers, Belgium). Cell culture plastic ware was from
Greiner (Frickenhausen, Germany). Monoclonal antibody (mAb)
FA6.152 directed against the OxLDL binding domain of human
CD36 was from Immunotech (Marseille, France). IV.3, a mAb against
human Fc gamma RII (CD32) was purchased as Fab fragments from
Medarex (Annandale, France). Both mAbs were purchased azide-free.
poH.4, a polyclonal antibody against platelet GPIIb/IIIa was previ-
ously prepared as described [13]. M-BSA was prepared as originally
described [14].
2.1. Lipoproteins
Extreme care was taken throughout all experimental procedures to
avoid inadvertent oxidation of LDL. All steps were performed at 4‡C
and EDTA was added to all solutions (except preceding copper oxi-
dation), resulting in a ¢nal concentration (f.c.) of 100 WM to prevent
oxidation by trace metal ions. Lipoproteins were used immediately
after preparation. Native LDL was rebu¡ered immediately before
use (PBS, 100 WM EDTA). Unless otherwise stated, rebu¡ering was
performed by gel ¢ltration (Econo-Pac 10DG Columns, Bio-Rad, CA,
USA).
Concentrations of lipoproteins are expressed in terms of their pro-
tein content as determined by the Lowry method [15].
2.2. Preparation of native LDL
LDL was isolated from normal human plasma (anti-coagulated
with 1/10 volume of 3.8% (w/v) trisodium citrate) immediately after
blood sampling by sequential centrifugation at 100 000Ug in the den-
sity range d = 1.019^1.063 g/ml [16] in the presence of 100 WM EDTA.
After £otation, the LDL was ¢ltered (0.45 Wm).
2.3. Acetylation of LDL
Acetylation was performed by the method of Basu et al. [17] on ice.
The reaction mixture was rebu¡ered after 1 h by gel ¢ltration.
2.4. Oxidation of LDL
After exhaustive dialysis of LDL against PBS to remove EDTA,
LDL (at a concentration of 200^250 Wg/ml) was incubated with
CuSO4 (5 Wmol/l f.c.) at 37‡C in borate bu¡er (0.1 M, pH = 7.2). After
24 h, the incubation was stopped and the lipoproteins were concen-
trated by the use of Ultrafree-15 with a MW cut-o¡ of 100 000 (Milli-
pore, Vienna, Austria) to a protein concentration of approximately
2000 Wg/ml. Subsequently, OxLDL was rebu¡ered (PBS, 0.1 M, 100
WM EDTA).
2.5. Radioiodination
Radioiodination of OxLDL was performed by the Iodo Bead meth-
od using N-chloro-benzenesulfonamide-conjugated polystyrene beads
(Pierce, Rockford, IL, USA) following the manufacturers instructions.
The speci¢c radioactivity of the labelled OxLDL species ranged from
150 to 250 cpm/ng protein.
2.6. Isolation of human platelets
Human platelets were isolated from freshly drawn blood as de-
scribed previously [18]. Brie£y, blood was anti-coagulated with 1/10
volume of 3.8% (w/v) trisodium citrate and centrifuged immediately at
120Ug for 20 min to yield platelet rich plasma. Prostacyclin (PGI2)
was added at f.c. of 25 Wg/l. Platelets were pelleted at 800Ug for 5 min
and resuspended with Tyrode bu¡er without Ca2 (NaCl 137 mM,
KCl 2.7 mM, NaHCO3 11.9 mM, MgCl2 1.0 mM, NaH2PO4 0.42
mM, D-glucose 5.5 mM, human serum albumin 3.5 g/l, PGI2 25 Wg/l,
pH 6.5). This washing procedure was repeated twice and the ¢nal
resuspension of the platelet pellet was performed with Tyrode bu¡er
containing 2 mM CaCl2 (Tyrode-Ca2), pH 7.35, without PGI2. After
isolation, the platelet suspension was immediately chilled on ice for at
least 30 min before performing the binding assays.
2.7. Cell culture
Murine macrophage J774A.1 and human monocytic THP-1 cells
were obtained from the European Collection of Cell Cultures
(ECACC) and cultured in the recommended media (DMEM and
RPMI 1640, respectively, as basal media) in the presence of penicillin
(100 U/ml) and streptomycin (100 Wg/ml) under the conditions given
by ECACC.
Before performing binding studies, THP-1 was di¡erentiated for
three days by use of 64 nM phorbol myristate acetate (Sigma) as
described [19].
2.8. Binding studies
To make the obtained data comparable between platelets and the
monocyte macrophage cell lines, all binding studies were performed in
PBS (with 2 mM CaCl2 added, pH = 7.35) for 3 h on ice. Albumin was
present throughout the incubation procedure at a concentration of
0.1%. After incubation with the labelled OxLDL, platelet suspensions
were centrifuged through a prechilled 1:3 dilution of Ficoll-Paque
(Amersham Pharmacia Biotech, Uppsala, Sweden) in saline. The
supernatants (representing the unbound OxLDL fraction) were aspi-
rated and the tips containing the pellets (representing the bound
OxLDL fraction) were cut o¡ using a hot wire [18].
J774A.1 and THP-1 cells were incubated with lipoproteins in 24
wells under the above described conditions. Supernatants were aspi-
rated and collected. The cell monolayer was washed three times and
the washing £uids were pooled with the previously aspirated super-
natants. Cells were lysed using 0.2 M NaOH.
Bound and unbound fractions were counted in a Cobra II gamma
counter (Canberra Industries, Meriden, CT, USA).
Non-speci¢c binding was determined by adding a 20-fold excess of
unlabelled OxLDL to the incubation mixture and was usually between
10 and 20% of the total binding.
Trichloroacetic acid-soluble degradation products were assessed as
previously described [20]
3. Results and discussion
The aim of this study was to compare the behavior of
AcLDL and OxLDL when they were binding to human plate-
lets. As there are no data available about the existence of
AcLDL binding receptors on the platelet membrane and as
human platelets bear two receptors (namely CD36 and CD32)
that have been described as potentially exclusive OxLDL re-
ceptors in transfected cells [19,21], we speculated about a dif-
ferent binding behavior of OxLDL and AcLDL to human
platelets compared to other cell types.
In general, macrophages are considered the ‘classic’ SR-
bearing cell type and are a recognized model for the exami-
nation of modi¢ed LDL binding.
For this reason, results gained using human platelets were
compared with those from similar experiments using the mur-
ine macrophage cell line J774A.1, as J774A.1 is probably the
best studied cell line in terms of its interaction with modi¢ed
LDL.
Binding experiments reveal a speci¢c binding of both
OxLDL and AcLDL to J774A.1 macrophages with a Kd of
1.95 þ 0.17 Wg/ml and 2.88 þ 0.6 Wg/ml, respectively. Analo-
gous studies carried out on human platelets are also able to
demonstrate a saturable, high a⁄nity binding of OxLDL to
this cell type, which is in accordance with previously pub-
lished data [19,22].
The a⁄nity of the observed OxLDL binding to human
platelets (Kd = 4.17 þ 0.8 Wg/ml) is within the range of that
obtained with J774A.1 cells. Approximately 3674 þ 460 bind-
ing sites per platelet can be found and the data gathered tend
to indicate a single class of receptors (not shown). However,
this does not preclude the existence of several types of OxLDL
binding receptors as virtually all presently known SRs display
a similar degree of a⁄nity to modi¢ed LDL.
In marked contrast to results attained using macrophages,
no speci¢c binding of AcLDL to platelets can be observed, a
clear indication of the absence of ‘classic’ SRs (SR-AI/AII) in
the platelet membrane.
Accordingly, AcLDL, as shown in Fig. 1, is not able to
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compete with platelet bound OxLDL, a ¢nding that is cor-
roborated by recently published data [19], as is the fact for
AcLDL that can partly compete with the binding of OxLDL
to the macrophages [2]. Native LDL does not appear to have
any in£uence on the binding of OxLDL in either of the in-
vestigated cell types.
To more thoroughly investigate the binding properties of
platelet OxLDL receptors, established antagonists of currently
classi¢ed SRs were used. As shown in Fig. 2, maleylated al-
bumin (an antagonist of OxLDL binding to SRs of both class
A and B) is capable of e¡ectively competing with the binding
of OxLDL to both cell types, essentially reducing OxLDL
binding to both platelets and J774A.1 macrophages to back-
ground levels.
In contrast, fucoidan (as polyinosinic acid, not shown), a
selective inhibitor of OxLDL binding to SRs of class A, is
only capable of exercising an inhibitory in£uence on the bind-
ing of OxLDL in J774A.1 cells (reducing binding to 36 þ 8%).
In human platelets, an increase rather than a decrease in the
OxLDL binding can be observed.
Both the inability of fucoidan to compete with the OxLDL
binding to human platelets and the fact that platelets show no
binding speci¢city for AcLDL provide compelling evidence
for a lack of class A SRs on human platelets.
Instead, all data presented clearly argue for an involvement
of class B SRs in OxLDL binding to human platelets. Inter-
estingly, even the observed increase of modi¢ed LDL binding
in the presence of fucoidan has been observed in this class of
receptors [23].
SRs of class B consist of two members, namely SR-BI and
CD36. While it is generally accepted that SR-BI shows spe-
ci¢city for AcLDL (which also competes with OxLDL for
binding to this receptor), it could be shown by several groups
that in the case of CD36, there would seem to be an exclusive
ligand speci¢city for OxLDL [19].[24,25] However, there are
¢ndings that seem to contradict this [23,26,27].
Fig. 1. In£uence of native LDL (b), AcLDL (R) and OxLDL (F) on the total binding of 125I-OxLDL (10 Wg/ml) to human platelets and
J774A.1 cells. Each data point represents the mean of three experiments in duplicate þ standard deviation (S.D.).
Fig. 2. Speci¢c binding of 125I-OxLDL (10 Wg/ml) to human plate-
lets and J774A.1 cells in the absence and presence of the SR antag-
onists fucoidan and M-BSA (50 Wg/ml each). Data represent the
mean of four experiments in duplicate þ S.D.
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CD36 is identical with GPIV [28] and was located as such
in the platelet membrane quite some time ago where it func-
tions as a thrombospondin and collagen receptor. The fact
that CD36 has been proven to be present in the platelet mem-
brane and in view of the above-mentioned results, CD36
would seem to be a prime candidate for the platelet OxLDL
receptor.
Therefore, the in£uence of the mAb FA6.152 on the
OxLDL binding to human platelets was of special interest,
as this antibody is directed against the OxLDL binding do-
main of CD36 (155^183). As the binding region of CD36 for
OxLDL di¡ers in human and murine membrane proteins [29]
and as respective antibodies are only able to compete with
OxLDL when binding to human, but not to murine CD36
[19,29], the human monocyte cell line THP-1, that had been
di¡erentiated with PMA, was used for subsequent compara-
tive experiments instead of murine J774A.1 cells.
As shown in Fig. 3, FA6.152 is able to reduce the speci¢c
OxLDL binding to human platelets to 7 þ 3.5%, which seems
to suggest an essential (if not exclusive) role for CD36 as the
platelet OxLDL receptor. In THP-1 cells, FA6.152 hinders
about 35% of the OxLDL binding, which is in accordance
with the reported contribution of CD36 to the overall binding
of OxLDL to this cell type [19,24,25].
As also shown in Fig. 3, the polyclonal antibody poH.4
directed against GPIIb/IIIa does not interfere with the binding
of OxLDL. This is of special interest as GPIIb/IIIa is the
platelet receptor not only for adhesive proteins such as ¢bri-
nogen and ¢bronectin, but also for native LDL [30]. As poH.4
has recently been shown to block the binding of native LDL
to human platelets [13], this, although consistent with the
results shown in Fig. 1, represents an important ¢nding, as
it clearly disputes the suggested role of GPIIb/IIIa as a recep-
tor for both native and OxLDL [22].
Additional studies were performed with Fab fragments of
IV.3, a mAb directed against human CD32 (Fc gamma RIIA)
able to block the binding of monomeric IgG and IgG immune
complexes to this receptor. The ¢nding that IV.3 does not
interfere with the OxLDL binding to both investigated cell
types rules out the possibility that the observed inhibition of
OxLDL binding to human platelets in the presence of
FA6.152 might (also) be caused by blocking the binding of
OxLDL to CD32 through the Fc portion of the anti-CD36
antibody.
This is of particular interest as the murine counterpart of
this receptor (namely Fc gamma RIIB) has been reported to
represent an OxLDL receptor [21], although this ¢nding could
only be substantiated in transfected but not in natural cells.
Of course, on the basis of the available data, it cannot be
precluded that platelet CD32 binds OxLDL through epitopes
not related to Fc and IV.3 binding. However, ¢ndings exist
that human CD32 is not involved in the xLDL binding [31]
and from the data presented in this study, the contribution of
CD32 to the OxLDL binding can be assumed to be minimal,
at best.
The results presented here allow for the ¢rst time the iden-
ti¢cation of a natural cell type capable of exclusively binding
OxLDL without showing speci¢city for AcLDL. Evidence of
exclusive OxLDL binding is particularly interesting as AcLDL
and OxLDL are sometimes considered to be equivalent lig-
ands in relation to the SR system. Consequently, AcLDL
(having the advantage of not being toxic) is often used to
assess the contribution of SRs to di¡erent (patho)physiolog-
ical processes.
Recently published ¢ndings obtained with CD36-trans-
fected cells have produced con£icting statements on the ques-
tion of whether CD36 is able to bind both OxLDL and
AcLDL or whether it acts as an exclusive OxLDL receptor.
The reasons for these controversial ¢ndings remain unclear.
One possibility put forward suggests the involvement of as yet
unidenti¢ed co-factors [25], although possible variations with-
in CD36 itself should perhaps be ¢rst more closely examined.
CD36 is a heavily glycosylated protein and it is known that
the Mr values for CD36 strongly di¡er between various cell
types within the same species as a consequence of a di¡erent
degree of cell type speci¢c glycosylation.
It therefore cannot be discounted that the degree of glyco-
sylation might interfere with the binding of some ligands to
CD36, either directly or due to changes of the quarternary
structure of the receptor protein. This gives rise to the intrigu-
ing possibility that the controversial nature of the ¢ndings
might be the result of post-translational events in di¡erent
cell types. Taking this into account, it could well be expected
that the binding speci¢city of CD36 expressed not only in
transfected cells but possibly also in di¡erent tissues may dif-
fer from the results shown here for human platelets.
Interestingly, there also seems to be a di¡erence with regard
to post-binding events triggered by platelet CD36 and CD36
expressed by transfected cell lines. Following the binding of
OxLDL to this receptor, transfected cells have been reported
to internalise and degrade OxLDL [19,24]. Although human
platelets are capable of endocytosis in principle, we do not
¢nd any trichloroacetic acid-soluble degradation products fol-
lowing incubation with 125I-OxLDL for so long as the full
Fig. 3. Speci¢c binding of 125I-OxLDL (10 Wg/ml) to human plate-
lets and di¡erentiated THP-1 cells in the presence of mAbs
FA6.152, IV.3 and the polyclonal antibody poH.4 (anti-CD36,
CD32 and platelet GPIIb/IIIa, respectively, f.c. : 4 Wg/ml each).
Data represent the mean of four experiments in duplicate þ S.D.
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functionality of the isolated platelets is preserved (approxi-
mately 2 h). Nevertheless, this period of time was su⁄cient
for J774A.1 macrophages to degrade 460 þ 72 ng of OxLDL/
mg of cell protein when incubated with 5 Wg/ml OxLDL. This
¢nding, together with the fact that the same amount of plate-
let bound 125I-OxLDL can be displaced by the subsequent
addition of unlabelled OxLDL at both 4‡C and 37‡C (not
shown), is a strong argument for an inability of platelet
CD36 to internalise (and degrade) OxLDL.
However, apart from the above suggested explanations sug-
gesting CD36 heterogeneity, the possibility remains that the
observed AcLDL binding by CD36-transfected cells might not
solely be a consequence of di¡erences within the receptor
protein, but (also) regarding the ligand, i.e. AcLDL.
It could be shown that an even comparatively modest oxi-
dation of LDL is adequate to e¡ect the binding speci¢city for
CD36 [19]. However, as even lightly oxidized AcLDL shows
speci¢city for CD36 (unpublished results), the possibility re-
mains that some AcLDL preparations do acquire binding
speci¢city through inadvertent oxidation (in the course of iso-
lation, acetylation or labelling) rather than by acetylation.
Further studies will be necessary to establish whether the
binding speci¢city of platelet CD36 described here is also true
for CD36 expressed by other natural cells. In any case, the
identi¢cation of an exclusive OxLDL receptor demands a crit-
ical reassessment of some of the ¢ndings previously obtained
in functional studies using AcLDL.
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